Stock Scan March 2018: Trading Down, Pairing Up
Merger and acquisition, or collaboration at least, was in the air during March as big pharma took stock of its opportunities in the midst of a disturbed market.
You may also be interested in...
As Takeda discloses that it is considering making a bid to acquire Shire, other big pharma companies look likely to assess their own interest in the firm. Pfizer and AbbVie are among those that may lay their cards on the table.
Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.
Sigurdur Olafsson is impressed with the balance sheet he has inherited at Hikma and said he is looking forward to both organic and inorganic growth.